<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
CURRENT REPORT FOR ISSUERS SUBJECT TO THE
1934 REPORTING REQUIREMENTS
FORM 8-K
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) September 12, 2000
------------------
KING PHARMACEUTICALS, INC.
--------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Tennessee 0--24425 54-1684963
--------------------------------------------------------------------------------
(State or other jurisdiction Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)
501 Fifth Street, Bristol, Tennessee 37620
--------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (423) 989-8000
--------------
Not Applicable
--------------------------------------------------------------------------------
(Former name, former address and former fiscal year,
if changed since last report)
<PAGE> 2
INFORMATION TO BE INCLUDED IN THE REPORT
ITEM 5. OTHER EVENTS.
On September 12, 2000 King Pharmaceuticals, Inc. announced changes to
its management team. A press release relating to these events was issued on
September 12, 2000.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(a) Financial Statements on Businesses Acquired.
None.
(b) Pro Forma Financial Information.
None.
(c) Exhibits.
The following exhibits are filed pursuant to Item 601 of
Regulation S-K:
Exhibit
Number Description
------ -----------
99.0 Press Release of King Pharmaceuticals, Inc. dated September 12,
2000.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
KING PHARMACEUTICALS, INC.
Date: September 12, 2000
By: /s/ John M. Gregory
--------------------------------------
John M. Gregory
Chairman of the Board and
Chief Executive Officer
- 1 -
